王彩艷，女，1987年生，博士，現(xiàn)任廣州中醫(yī)藥大學(xué)中藥學(xué)院國(guó)際中醫(yī)藥轉(zhuǎn)化醫(yī)學(xué)研究所研究員，博士生導(dǎo)師，國(guó)家優(yōu)秀青年科學(xué)基金獲得者，“青年珠江學(xué)者”稱號(hào)獲得者，中藥學(xué)學(xué)科后備帶頭人。致力于中藥抗炎的結(jié)構(gòu)藥理學(xué)研究，聚焦中藥苯丙素類(lèi)成分作用靶點(diǎn)的確證及機(jī)制解析，以第一和通訊（含共同）作者在Science advances、Nucleic Acids Research、Theranostics、Acta Pharmacologica Sinica等雜志上發(fā)表中藥藥效成分的結(jié)構(gòu)藥理學(xué)基礎(chǔ)研究性論文28篇，其中通訊作者論文20篇，獲得國(guó)家自然科學(xué)基金面上項(xiàng)目、青年項(xiàng)目，廣東省教育廳和廣東省科技廳等9項(xiàng)課題。承擔(dān)《藥理學(xué)》、《藥物毒理學(xué)》和《結(jié)構(gòu)生物學(xué)與現(xiàn)代藥學(xué)研究》本科生課程，承擔(dān)《藥學(xué)專論》研究生課程，參編“十四五”規(guī)劃教材《藥物毒理學(xué)》。

教育工作經(jīng)歷： 

2015年，畢業(yè)于中山大學(xué)生物化學(xué)與分子生物學(xué)專業(yè)，獲博士學(xué)位，

2015年，中山大學(xué)“有害生物控制與資源利用國(guó)家重點(diǎn)實(shí)驗(yàn)室”從事博士后研究。

2017年以“杏林青年學(xué)者”身份引進(jìn)到廣州中醫(yī)藥大學(xué)工作至今。 

2019年美國(guó)加州大學(xué)洛杉磯分校分子成像中心訪問(wèn)學(xué)者。

     

主講課程： 

本科生教學(xué):《藥理學(xué)》《藥物毒理學(xué)》和《結(jié)構(gòu)生物學(xué)與現(xiàn)代藥學(xué)研究》； 

研究生教學(xué):《藥學(xué)專論》的蛋白質(zhì)結(jié)構(gòu)藥理學(xué)部分。

 

研究領(lǐng)域：

中藥抗炎結(jié)構(gòu)藥理學(xué) 

研究方向：應(yīng)用結(jié)構(gòu)生物學(xué)等方法研究藥理學(xué)，從原子水平闡明藥物的作用機(jī)制，為合理藥物設(shè)計(jì)奠定基礎(chǔ)。重大疾病相關(guān)蛋白質(zhì)的結(jié)構(gòu)生物學(xué)、基于結(jié)構(gòu)的藥物設(shè)計(jì)與發(fā)現(xiàn)、基于蛋白質(zhì)結(jié)構(gòu)的天然藥物作用靶點(diǎn)和機(jī)制研究。

（1）中藥藥效分子作用靶點(diǎn)發(fā)現(xiàn)與確證； 

（2）基于“成分-靶點(diǎn)”互作結(jié)構(gòu)的抗炎機(jī)制解析。 

科研及教學(xué)課題： 主持國(guó)家科學(xué)自然基金、廣東省基礎(chǔ)與應(yīng)用基礎(chǔ)研究專項(xiàng)資金、中國(guó)博士后基金、“2017年博士后國(guó)際交流計(jì)劃”等科研基金項(xiàng)目。

1. 國(guó)家自然科學(xué)基金優(yōu)秀青年科學(xué)基金項(xiàng)目，82322074， 2024/01-2026/12，200萬(wàn)元，主持，在研。 

2. 廣州中醫(yī)藥大學(xué)青年拔尖人才 (團(tuán)隊(duì)) 培育“揭榜掛帥”項(xiàng)目，2023/09-2026/09，50萬(wàn)元，主持，在研。 

3. 國(guó)家自然科學(xué)基金面上項(xiàng)目，82274214，2023/01-2026/12，52萬(wàn)元，主持，在研。 

4. 廣東省教育廳重點(diǎn)領(lǐng)域項(xiàng)目，2022ZDZX2010，2023/01-2025/12，10萬(wàn)元，主持，在研。 

5. 廣州市基礎(chǔ)與應(yīng)用基礎(chǔ)研究項(xiàng)目，202201011420，2022/04-2024/03，5萬(wàn)元，主持，在研。 

6.廣州中醫(yī)藥大學(xué)“杏林青年學(xué)者”啟動(dòng)經(jīng)費(fèi)，2017/07-2020/06,  100 萬(wàn)，主持，結(jié)題。

7. 廣州中醫(yī)藥大學(xué)“青年科研培育項(xiàng)目”，2019/05-2021/05，30 萬(wàn)，主持，結(jié)題。 

6. 廣東省教育廳，2019年廣東省高等學(xué)校青年珠江學(xué)者，2019/10-2022/09, 100萬(wàn)，主持，結(jié)題。 

7. 國(guó)家自然科學(xué)基金青年項(xiàng)目，31700625，雙加氧酶 AlkBH1 調(diào)控翻譯起始 tRNA(iMet) m1A58 去甲基化的結(jié)構(gòu)及生化性質(zhì)研究，2018/01-2020/12，24萬(wàn)元，主持，結(jié)題。 

8. 廣東省基礎(chǔ)與應(yīng)用基礎(chǔ)面上項(xiàng)目，2017A030310190，應(yīng)激條件下磷酸化激酶 GCN2 激活的結(jié)構(gòu)基礎(chǔ)，2017/05-2020/5，10萬(wàn)元，主持，結(jié)題。 

9. 中國(guó)博士后科學(xué)基金特別資助，2017T100654，雙加氧酶 AlkBH1 調(diào)控翻譯起始的結(jié)構(gòu)基礎(chǔ)，2017/01-2017/06，15萬(wàn)元，主持，結(jié)題。

發(fā)明專利：

[1]王彩艷, 范敏棋, 許遠(yuǎn)航, 張英, 吳芳, 張林. 一種可去除標(biāo)簽的載體及其構(gòu)建方法與應(yīng)用[P]. 廣東省: CN117535329A, 2024-02-09.

[2]廖國(guó)超, 劉中秋, 楊德盈, 高玲強(qiáng), 練慶海, 吳鵬, 蘇詩(shī)薇, 曾莉茗, 盧琳琳, 王彩艷. 一種含有單磷酸化的脂質(zhì)A與糖抗原的綴合物及其制備方法和應(yīng)用[P]. 廣東省: CN111588847B, 2023-05-26.

[3]廖國(guó)超, 劉中秋, 楊德盈, 練慶海, 高玲強(qiáng), 吳鵬, 蘇詩(shī)薇, 曾莉茗, 盧琳琳, 王彩艷. 一種綴合物及其制備方法和應(yīng)用[P]. 廣東省: CN111760020B, 2023-05-26.

[4]劉中秋, 廖國(guó)超, 王彩艷, 廖宗浪, 喻琦, 劉丹, 謝薇, 盧琳琳, 吳鵬, 楊德盈. 一種吲哚類(lèi)生物堿化合物及其制備方法和應(yīng)用[P]. 廣東省: CN111808100B, 2021-10-12.

[5]劉中秋, 吳鵬, 廖國(guó)超, 周華, 王彩艷, 梁麗嫻. 一種E環(huán)開(kāi)裂的烏蘇烷型三萜皂苷類(lèi)化合物的用途[P]. 廣東省: CN109045051B, 2021-05-07.

[6]劉中秋, 廖國(guó)超, 王彩艷, 廖宗浪, 喻琦, 劉丹, 謝薇, 盧琳琳, 吳鵬, 楊德盈. 一種吲哚類(lèi)生物堿化合物及其制備方法和應(yīng)用[P]. 廣東省: CN111808100A, 2020-10-23.

[7]廖國(guó)超, 劉中秋, 楊德盈, 練慶海, 高玲強(qiáng), 吳鵬, 蘇詩(shī)薇, 曾莉茗, 盧琳琳, 王彩艷. 一種綴合物及其制備方法和應(yīng)用[P]. 廣東省: CN111760020A, 2020-10-13.

[8]劉中秋, 廖國(guó)超, 柯昌文, 戚笑笑, 柯碧霞, 楊得盈, 吳鵬, 盧琳琳, 馮潛, 王彩艷, 李自波. 一種SARS-CoV-2的融合蛋白及其疫苗組合物[P]. 廣東省: CN111662389A, 2020-09-15.

[9]廖國(guó)超, 劉中秋, 楊德盈, 高玲強(qiáng), 練慶海, 吳鵬, 蘇詩(shī)薇, 曾莉茗, 盧琳琳, 王彩艷. 一種含有單磷酸化的脂質(zhì)A與糖抗原的綴合物及其制備方法和應(yīng)用[P]. 廣東省: CN111588847A, 2020-08-28.

代表性論文： 以第一作者和通訊作者在Science Advances（IF=11.511）、Nucleic Acids Research（IF=11.561）等高水平期刊上發(fā)表研究論文多篇。 

1. Caiyan Wang#(王彩艷，第一作者), Xiaojun Teng, Chuang Wang, Binjie Liu, Runze Zhou, Xueyu Xu, Huawei Qiu, Yu Fu, Rongjin Sun, Zuhui Liang, Rong Zhang, Zhongqiu Liu*, Lin Zhang*, Lijun Zhu*. Insight into the mechanism of Xiao-Chai-Hu-Tang alleviates irinotecan-induced diarrhea based on regulating the gut microbiota and inhibiting Gut β-GUS. Phytomedicine, 2023, 120:155040. 

2. Huan Lan, Ying Zhang, Minqi Fan, Bingxin Wu, Caiyan Wang*(王彩艷，通訊作者). Pregnane X receptor as a therapeutic target for cholestatic liver injury. Drug metabolism reviews. 2023, 1-17. 

3. Fang Wu, Yuanyuan Cheng, Jianfu Zhou, Xuehua Liu, Rongwu Lin, Songtao Xiang, Zhongqiu Liu*, Caiyan Wang*(王彩艷，通訊作者).  Zn2+ regulates human oxalate metabolism by manipulating oxalate decarboxylase to treat calcium oxalate stones. Int J Biol Macromol. 2023, 15;234:123320. 

4. Zibo Li#, Lin Jiang#, Jiadong Ni, Yuanhang Xu, Fang Liu, Wenming Liu, Shaogui Wang*, Zhongqiu Liu*, Caiyan Wang*(王彩艷，通訊作者). Salvianolic acid B Suppresses Hepatic Fibrosis by Targeting Ceramide Glucosyltransferase in Hepatic Stellate Cells. Acta Pharmacologica Sinica, 2023, 44(6):1191-1205. 

5. Lin Zhang, Yuanhang Xu, Xuerong Zhang, Yibing Yang, Jiangyong Gu, Zhongqiu Liu*, Caiyan Wang*(王彩艷，通訊作者). The Structural Basis of Conserved Residue Variant Effect on Enzyme Activity of UGT2B15, BBA - Proteins and Proteomic, 2023, 1871(3):140888. 

6. Tian-Tian Wang#, Li-Chun Zhang#, Zhen Qin, Shu-Jun Chen , Jing-Min Zeng, Jing-Yan Li, Lin An, Cai-Yan Wang(王彩艷), Yong Gao, LiMing Wang, ZhongXiang Zhao*, ZhongQiu Liu*, Shao-Gui Wang*. Decreased syntaxin17 expression contributes to the pathogenesis of acute pancreatitis in murine models by impairing autophagic degradation. Acta Pharmacol Sin. 2023, doi: 10.1038/s41401-023-01139-x. 

7. Tao Su, Suchao Huang, Yanmin Zhang, Yajuan Guo, Shuwei Zhang, Jiaji Guan, Mingjing Meng, Linxin Liu, Caiyan Wang(王彩艷), Dihua Yu, Hiu-Yee Kwan, Zhiying Huang, Qiuju Huang, Elaine Lai-Han Leung, Ming Hu, Ying Wang, Zhongqiu Liu*, Linlin Lu*. miR-7/TGF-β2 axis sustains acidic tumor microenvironment-induced lung cancer metastasis. Acta Pharm Sin B. 2022 ;12(2):821-837. 

8. Juan Liu, Yuxin Zhuang, Jianlin Wu, Qiang Wu, Meixian Liu, Yue Zhao, Zhongqiu Liu, Caiyan Wang(王彩艷), Linlin Lu, Yingjiao Meng, Kawai Lei, Xiaojuan Li, Qibiao Wu, Elaine Lai-Han Leung, Zhengyang Guo, Liang Liu*, Ting Li*. IKKβ mediates homeostatic function in inflammation via competitively phosphorylating AMPK and IκBα. Acta Pharm Sin B.  2022, 12(2):651-664. 

9. Baoyuan Huang, Qiumei Wang, Lin Jiang, Shuru Lu, Chengcheng Li, Chunqi Xu, Caiyan Wang*(王彩艷，共同通訊作者), Enxin Zhang*, Xiaojun Zhang*. Shikonin ameliorated mice colitis by inhibiting dimerization and tetramerization of PKM2 in macrophages. Frontiers in Pharmacology, 2022, 17;13:926945. 

10. Xuerong Zhang, Shehan Li, Zibo Li, Liangkai Cheng, Zhongqiu Liu, Caiyan Wang*(王彩艷，通訊作者). The therapeutic potential of targeting Hsp90-Cdc37 interactions in several diseases. Current Drug Targets, 2022. 23(10):1023-1038. 

11. Lin Zhang, Wei Xie, Xiaojun Teng, Kui Wang, Wei Xie*, Caiyan Wang*(王彩艷，通訊作者). Improving the Extraction of Active Ingredients from Medicinal Plants by XynA Modification. Journal of Chemistry, 2022, doi:10.1155/2022/2483797. 

12. Xuerong Zhang#, Shehan Li#, Zibo Li, Liangkai Cheng, Zhongqiu Liu*, Caiyan Wang*(王彩艷，通訊作者). The Therapeutic Potential of Targeting Hsp90-Cdc37 Interactions in Several Diseases. Current Drug Targets, 2022, 23(10):1023-1038. 

13. Zibo Li, Lin Zhang, Dan Liu, Caiyan Wang*(王彩艷，通訊作者). Ceramide glycosylation and related enzymes in cancer signaling and therapy. Biomedicine & Pharmacotherapy, 2021, 139:111565. 

14. Yuanyuan Cheng#, Liangkai Cheng#, Xiang Gao, Sixuan Chen, Peng Wu, Caiyan Wang*(王彩艷，共同通訊作者), Zhongqiu Liu*. Covalent modification of Keap1 at Cys77 and Cys434 by pubescenoside a suppresses oxidative stress-induced NLRP3 inflammasome activation in myocardial ischemia-reperfusion injury. Theranostics, 2021; 11(2): 861-877. 

15. Dan Liu，Qi Yu，Zibo Li，Lin Zhang，Ming Hu，Caiyan Wang*(王彩艷，共同通訊作者)，Zhongqiu Liu*, UGT1A1 dysfunction increases liver burden and aggravates hepatocyte damage caused by long-term bilirubin metabolism disorder, Biochemical Pharmacology, 2021, 190:114592. 

16. Liangkai Cheng, Huihui Wang, Shehan Li, Zhongqiu Liu, Caiyan Wang*(王彩艷，通訊作者). New insights into the mechanism of Keap1-Nrf2 interaction based on cancer-associated mutations, Life Sciences, 2021, 282:119791. 

17. Wei Xie, Qi Yu, Ruiqing Zhang, Yun Liu, Ruoting Cao, Sidi Wang, Ruoting Zhan, Zhongqiu Liu, Kui Wang*, Caiyan Wang*(王彩艷，通訊作者). Insights into the Catalytic Mechanism of a Novel XynA and Structure-Based Engineering for Improving Bifunctional Activities. Biochemistry，2021, 60(26):2071-2083. 

18. Ying Zhang, Caiyan Wang*(王彩艷，通訊作者). Demethyltransferase AlkBH1 Substrate Diversity and Relationship to Human Diseases. Molecular Biology Reports, 2021, 48(5):4747-4756. 

19. Wei Liu#, Yanxiang Cui#, Caiyan Wang (王彩艷), Zihang Li, Danyang Gong, Xinghong Dai, Guo-Qiang Bi, Ren Sun, Z Hong Zhou*. Structures of capsid and capsid-associated tegument complex inside the Epstein-Barr virus. Nature Microbiology, 2020, 5(10):1285-1298. 

20. Liangkai Cheng, Hong Zhang, Fang Wu, Zhongqiu Liu, Yuanyuan Cheng*, Caiyan Wang*(王彩艷，通訊作者). Role of Nrf2 and Its Activators in Cardiocerebral Vascular Disease. Oxidative Medicine and Cellular Longevity. 2020, 4683943. 

21. Lin Zhang#, Lijun Zhu#, Wei Qu, Fang Wu, Ming Hu, Wei Xei*, Zhongqiu Liu*, Caiyan Wang*(王彩艷，通訊作者). Insight into tartrate inhibition patterns in vitro and in vivo based on cocrystal structure with UDP-glucuronosyltransferase 2B15. Biochemical Pharmacology, 2020, 172:113753. 

22. Hong Li, Ying Zhang, Yajuan Guo, Rong Liu, Qi Yu, Lingzhi Gong, Zhongqiu Liu*, Wei Xie*, Caiyan Wang*(王彩艷，通訊作者). ALKBH1 Promotes Lung Cancer by Regulating m6A RNA Demethylation. Biochemical Pharmacology, 2020, 114284. 

23. Qi Yu, Zonglang Liao, Dan Liu, Wei Xie, Zhongqiu Liu, Guochao Liao*, Caiyan Wang*(王彩艷，通訊作者). Small molecule inhibitors of the prostate cancer target KMT2D. Biochemical and Biophysical Research Communications, 2020, 10;533(3):540-547. 

24. Dan Liu, Lin Zhang, Lixin Duan, Jinjun Wu, Ming Hu, Zhongqiu Liu*, Caiyan Wang*(王彩艷，通訊作者). Potential of Herb-Drug/Herb Interactions between Substrates and Inhibitors of UGTs Derived from Herbal Medicines. Pharmacological Research, 2019, 150:104510. 

25. Fang Wu, Liangkai Cheng, Qi Yu, Lin Zhang, Hong Li, Caiyan Wang**(王彩艷，通訊作者), Purification and functional characterization of the C-terminal domain of the β-actin-binding protein AIM1 in vitro, Molecules. 2018, 23(12): 3281. (2017 IF: IF=3.098; 5-year IF: IF=3.268; 分區(qū): Q3)

26. Caiyan Wang#(王彩艷，第一作者), Qian Jia#, Jianhua Zeng, Ran Chen, Wei Xie*. Structural insight into the methyltransfer mechanism of the bifunctional Trm5. Science Advances, 2017, 3(12):1-9.  (2017 IF: IF=11.511; 5-year IF: IF=11.511; 分區(qū): Q1)

27. Caiyan Wang(王彩艷，第一作者), Jianhua Zeng, Wei Xie*, A flexible cofactor-binding loop in the novel arginine methyltransferase Sfm1. FEBS Letters, 2017, 591(2):433-441. (2017 IF: IF=2.999; 5-year IF: IF= 3.373; 分區(qū): Q2)

28. Caiyan Wang(#), Yu Guo, Qingnan Tian, Qian Jia, Yuanzhu Gao, Qinfen Zhang, Chun Zhou, Wei Xie*, SerRS-tRNASec complex structures reveal mechanism of the first step in selenocysteine biosynthesis, Nucleic Acids Research, 2015, 43(21): 10534-10545. (2017 IF: IF=11.561; 5-year IF: IF= 10.235; 分區(qū): Q1)

29. Caiyan Wang(#), Qian Jia(#), Ran Chen, Yuming Wei, Juntao Li, Jie Ma, Wei Xie*, Crystal structures of the bifunctional tRNA methyltransferase Trm5a, Scientific Reports, 2016, 6: 33553. (2017 IF: IF=4.122; 5-year IF: IF= 4.609; 分區(qū): Q3)

30. Caiyan Wang#(王彩艷，第一作者), Qian Jia #, Ran Chen, Yuming Wei, Juntao Li, Jie Ma, Wei Xie*. Crystal structures of the bifunctional tRNA methyltransferase Trm5a. Scientific Reports, 2016, 6: 33553. 

31. Caiyan Wang(王彩艷，第一作者), Yu Guo, Qingnan Tian, Qian Jia, Yuanzhu Gao, Qinfen Zhang, Chun Zhou, Wei Xie*. SerRS-tRNASec complex structures reveal mechanism of the first step in selenocysteine biosynthesis. Nucleic Acids Research, 2015, 43(21): 10534-10545.

榮譽(yù)獎(jiǎng)勵(lì)：

1、國(guó)家優(yōu)秀青年科學(xué)基金獲得者。

2、2019年，“青年珠江學(xué)者”稱號(hào)獲得者。

3、廣州中醫(yī)藥大學(xué)“杏林青年學(xué)者”。

4、中藥學(xué)學(xué)科后備帶頭人。